Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2005;331 (1 October), doi:10.1136/bmj.331.7519.0-a
Guidelines for treating children with uncomplicated malaria changed in Zambia in 2002 in line with the best available evidence, but the change has not yet translated into adequate use at the point of care. A cross sectional study by Zurovac and colleagues (p 734) shows how artemether-lumefantrine, which should be the first choice of treatment for children weighing 10 kg or more, is not being prescribed even when available.
|
|
Credit: GIACOMO PIROZZI/PANOS
|
In a cluster randomised trial, Chandramohan and colleagues (p 727) showed that sulfadoxine-pyrimethamine can prevent malaria and anaemia in infants up to 15 months old. These children may also have a higher risk of high parasite density malaria after treatment is stopped, however.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
What can you learn from this BMJ paper? Read Leanne Tite's Paper+